Figure 5.
Mutations in tumor suppressor genes and oncogenes are expressed. (A) Scatterplot with oncogene and tumor suppressor gene exome and RNA-seq VAFs (r2 = 0.585). Translocation partner oncogene mutations are colored and are generally outliers with increased expression. (B) TP53 mutations, including missense, nonsense, and frameshift, are detectable according to VAF. High VAF on either axis is due to deletion of TP53 and is indicative of biallelic inactivation. (C) KRAS, NRAS, and BRAF mutations are expressed according to VAF. NRAS has more high VAF-expressed mutations (>0.5), because it is on 1p, and the nonmutated allele is frequently deleted. (D) NF-κB genes CYLD, NFKBIA, TRAF2, and TRAF3.

Mutations in tumor suppressor genes and oncogenes are expressed. (A) Scatterplot with oncogene and tumor suppressor gene exome and RNA-seq VAFs (r2 = 0.585). Translocation partner oncogene mutations are colored and are generally outliers with increased expression. (B) TP53 mutations, including missense, nonsense, and frameshift, are detectable according to VAF. High VAF on either axis is due to deletion of TP53 and is indicative of biallelic inactivation. (C) KRAS, NRAS, and BRAF mutations are expressed according to VAF. NRAS has more high VAF-expressed mutations (>0.5), because it is on 1p, and the nonmutated allele is frequently deleted. (D) NF-κB genes CYLD, NFKBIA, TRAF2, and TRAF3.

Close Modal

or Create an Account

Close Modal
Close Modal